VBI Vaccines, Inc. - Ordinary Shares (VBIV) News
Filter VBIV News Items
VBIV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VBIV News Highlights
- VBIV's 30 day story count now stands at 4.
- Over the past 14 days, the trend for VBIV's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BEAT and ABSI are the most mentioned tickers in articles about VBIV.
Latest VBIV News From Around the Web
Below are the latest news stories about VBI VACCINES INC that investors may wish to consider to help them evaluate VBIV as an investment opportunity.
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue EstimatesVBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -7.05% and 40.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
VBI Vaccines Reports First Quarter 2023 Financial ResultsCAMBRIDGE, Mass., May 15, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023. |
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseAbsci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseVBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
VBI Vaccines Appoints Vaughn Himes to Board of DirectorsCAMBRIDGE, Mass., April 25, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical compan |
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring PlansVBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split. |
VBI Vaccines Announces Cost Cutting Measures, Reverse Stock SplitVBI Vaccines Inc (NASDAQ: VBIV) plans to focus concentrating on broadening access to VBI's FDA-approved 3-antigen HBV vaccine for adults, PreHevbrio [Hepatitis B Vaccine (Recombinant)], and advancing its HBV immunotherapeutic candidate, VBI-2601. The company will reduce its internal workforce by 30-35% – a reduction expected to begin in April and be complete by the end of June 2023. VBI also expects its operating expenses from normal business to be 30-35% lower in the second half of 2023 than in |
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock SplitCAMBRIDGE, Mass., April 04, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts on the fight against hepatitis B (HBV), concentrating on broadening access to VBI’s FDA-approved 3-antigen HBV vaccine for adults, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], and advancing its HBV immunotherapeutic candidate, VBI-2601, which has the poten |
VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsVBI Vaccines ( NASDAQ:VBIV ) Full Year 2022 Results Key Financial Results Net loss: US$113.3m (loss widened by 62% from... |
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue EstimatesVBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |